QIAreach SARS-CoV-2 antigen test, developed in collaboration with Ellume, is easy to use and provides accurate and objective results in 2 to 15 minutes
The drug is indicated for mild and transient episodes of heart block
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
The government has recently enhanced the incentive granted to storeowners from existing Rs. 2.50 lakh to Rs. 5.00 lakh given at the rate of 15% of monthly purchases made, subject to a ceiling of Rs. 15,000 per month
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
Filing for WHO Emergency Use Authorisation this month
Subscribe To Our Newsletter & Stay Updated
